Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
Related Posts
Nagarajan P, Kurniansyah N, Lee J, Gharib SA, Xu Y, Zhang Y, Spitzer B, Faquih T, Zhou H, Boerwinkle E, Chen H, Gottlieb DJ, Guo[...]
Cunha J, Domingo A, Kolkhorst FW, Rossiter HB, Cannon DT. Imposed expiratory resistance, dynamic hyperinflation and locomotor power and fatigue. Exp Physiol. 2025 Jul 30.[...]
Hayat A, Johnson DW, Manera K, Viecelli AK, Wilkie M, Shen J, Wang AY, Htay H, Jaure A, Cho Y, Walker R. Experiences and perspectives[...]